Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects

BACKGROUND: Remdesivir is the first antiviral drug against SARS-CoV-2 approved for use in COVID-19 patients. OBJECTIVES: To study the pharmacokinetic inter-individual variability of remdesivir and its main metabolite GS-441524 in a real-world setting of COVID-19 inpatients and to identify possible a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tempestilli, Massimo, Ascoli Bartoli, Tommaso, Benvenuto, Domenico, Stazi, Giulia Valeria, Marchioni, Luisa, Nicastri, Emanuele, Agrati, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384469/
https://www.ncbi.nlm.nih.gov/pubmed/35848782
http://dx.doi.org/10.1093/jac/dkac234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384469/
https://www.ncbi.nlm.nih.gov/pubmed/35848782
http://dx.doi.org/10.1093/jac/dkac234

Ejemplares similares